December 11, 2019

December 11, 2019

Subscribe to Latest Legal News and Analysis

December 10, 2019

Subscribe to Latest Legal News and Analysis

December 09, 2019

Subscribe to Latest Legal News and Analysis

CMS Finalizes Prior Authorization Program for Certain DMEPOS Items

On December 30, 2015, the Centers for Medicare & Medicaid Services (CMS) published its final rule establishing a prior authorization program for certain durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) items frequently subject to unnecessary utilization (the Final Rule). As noted in our commentary on the proposed rule  the Final Rule creates a “Master List” of items that could require prior authorization as a condition of Medicare payment as well as a subset list of items for which prior authorization is required. The provisions of the Final Rule are effective on February 29, 2016.

Master List

The Master List of DMEPOS items that could be subject to prior authorization includes items frequently subject to “unnecessary utilization,” which is defined as “the furnishing of items that do not comply with one or more of Medicare’s coverage, coding, and payment rules.”  The Final Rule creates an initial Master List of 135 items that are listed on the DMEPOS fee schedule with an average purchase fee of $1,000 or greater or an average rental fee schedule of $100 or greater, and meet one of the following two criteria:

  • Identified as having a high rate of fraud or unnecessary utilization by any Office of Inspector General (OIG) or General Accountability Office (GAO) report of national scope published in 2007 or later; or

  • Listed in the 2011 or later Comprehensive Error Rate Testing (CERT) program’s Annual Medicare Fee-For-Service (FFS) Improper Payment Rate Report Durable Medical Equipment (DME) and/or DMEPOS Service Specific Report(s).

The Master List will be updated annually and published in the Federal Register. Items will be aged-off the list after 10 years unless a subsequent OIG or GAO report identifies the item as having a high rate of unnecessary utilization. Items will also be removed from the Master List if they are discontinued, no longer covered by Medicare, or if the purchase amount drops below the payment thresholds described above. If the Healthcare Common Procedure Coding System (HCPCS) code representing a listed item is discontinued, the item will be updated and replaced with the equivalent item and code.

Required Prior Authorization List

As proposed, prior authorization is not required for all items on the Master List. Instead, CMS will create a Required Prior Authorization List comprised of a subset of items on the Master List. Many commenters to the proposed rule voiced concern regarding CMS’ decision not to identify which of the Master List items would be subject to prior authorization. In response, CMS stated its selection of items for the Required Prior Authorization List will be guided by factors such as geographic location, item utilization or cost, system capabilities, administrative burden, emerging trends, vulnerabilities identified in official agency reports or other data analysis. CMS also finalized its proposal to allow for national or local implementation of the prior authorization requirement based on geographic trends of unnecessary utilization in claims data analysis. CMS will publish the Required Prior Authorization List in the Federal Register 60 days before requiring prior authorization and will engage in other “education and community interaction[s]” to provide notice to suppliers.

Prior Authorization Process

Under the Final Rule, authorization requests must be submitted prior to furnishing the item and prior to submitting the claim for payment processing. Following submission, CMS or its contractors will conduct a medical review and communicate a provisional decision. In the event of a non-affirmative decision, unlimited resubmissions are allowed to correct errors and comply with documentation requirements. Expedited review requests are available but require documentation to demonstrate that the standard authorization process may “seriously jeopardize the life or health of the beneficiary or the beneficiary’s ability to regain maximum function.”  The Final Rule does not adopt the proposed approval or turnaround timeframes, citing potential access concerns highlighted in public commentary. To maintain “flexibility,” CMS will publish sub-regulatory guidance to implement the Final Rule and address the “operational logistics of the prior authorization process,” including timeframe and other submission requirements, at a later date.

In the Final Rule, CMS retains its position expressed in the proposed rule that a denial of prior authorization is not considered an initial determination for a claim of payment and, as a result, will not be appealable. An item on the Required Prior Authorization List that is submitted without an affirmative prior authorization decision will be automatically denied payment. Therefore, prior authorization is a condition of payment, but does not necessarily guarantee payment. Information that is only available after the claim is submitted may result in denial (e.g., duplicate claim, absent or improperly listed delivery date).


Although CMS will provide suppliers with 60 days’ notice in the Federal Register before requiring prior authorization for new items, DMEPOS suppliers of Master List items should regularly take note whether items are included on the Required Prior Authorization List and update internal administrative and claims processes accordingly. Failure to do so puts DMEPOS suppliers at risk for claim denials related to items subject to prior authorization.

© 2019 McDermott Will & Emery


About this Author

Monica Wallace, regulatory counseling lawyer, administrative attorney, McDermott Will Emery, law firm

Monica A. Wallace is an associate in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Chicago office.  She focuses her practice on complex regulatory and transactional counseling to health care organizations such as health systems, hospitals, physician groups, integrated delivery systems, durable medical equipment prosthetics and orthotics suppliers, home health agencies, and other health care providers. Monica’s regulatory practice focuses on the Anti-Kickback and Stark laws; Medicare and Medicaid reimbursement and billing; legal assessments and compliance...

Emily J. Cook, McDermott Will Emery Law Firm, Health Care Attorney

Emily J. Cook is an associate in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Los Angeles office.  She focuses her practice on Medicare provider certification, reimbursement and regulatory compliance.


Jessica M. Jung is an associate in the law firm of McDermott Will & Emery and is based in the Firm’s Los Angeles office. She focuses her practice on transactional and regulatory matters affecting a wide range of clients in the health care industry.

Jessica received her J.D. from Harvard Law School in 2015 and B.A. in economics, summa cum laude, from the University of Pennsylvania in 2012.

Jessica is a member of the American Health Lawyers Association.

Jessica is admitted to...

310 284 6179
Joan Polacheck, Health Care industry Lawyer, McDermott Will Emery, Chicago Law Firm

Joan Polacheck is a partner in the law firm of McDermott Will & Emery LLP and is based in the Firm’s Chicago office. She represents a broad range of health care industry clients, including hospitals, suppliers, and drug and device companies.